Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy

In brief

The purpose of this study is to determine if erlotinib will improve disease at doses that produce its characteristic rash in patients with advanced Non-Small Cell Lung Cancer.

Key facts

Study ID

NCT00072631

Run by

OSI Pharmaceuticals

People needed

43

Starts

2003-11-05

Expected to finish

2007-03-14

Last updated by the study team

2018-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of Stage IIIB or IV non-small cell lung cancer (histological or cytological).
• Received prior chemotherapy treatment for advanced, metastatic non-small cell lung cancer.
• Measurable disease per RECIST criteria.
• Adequate bone marrow, hepatic and renal function.

You may not qualify if…

• Breast cancer or skin cancer at any time in the past or any other cancer in the past 5 years.
• Brain metastases that are unstable, require steroids, are life-threatening or required radiation in the last 28 days.
• Known hypersensitivity to minocycline.
• History of serious cardiac disease that is not controlled.
• Serious eye conditions.
• Prior treatment with inhibitors of EGFR of any kind.

Where it is running

• Institute for Drug Development Cancer Therapy and Research Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.